Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IFRX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

InflaRx N.V.

IFRX
Current price
0.87 USD +0.018 USD (+2.11%)
Last closed 0.81 USD
ISIN NL0012661870
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 58 797 712 USD
Yield for 12 month -45.42 %
1Y
3Y
5Y
10Y
15Y
IFRX
21.11.2021 - 28.11.2021

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.71 USD

P/E Ratio

Dividend Yield

Financials IFRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+192 108 USD

Last Year

+73 104 USD

Current Quarter

Last Quarter

-490 USD

Current Year

-3 651 502 USD

Last Year

-543 653 USD

Current Quarter

-10 766 USD

Last Quarter

-3 269 223 USD
EBITDA -53 479 384 USD
Operating Margin TTM -41 252.01 %
Price to Earnings
Return On Assets TTM -34.47 %
PEG Ratio
Return On Equity TTM -54.13 %
Wall Street Target Price 3.71 USD
Revenue TTM 129 752 USD
Book Value 1.04 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 103.60 %
Dividend Yield
Gross Profit TTM -2 976 057 USD
Earnings per share -0.87 USD
Diluted Eps TTM -0.87 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation IFRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 72.13
Price Sales TTM 453.15
Enterprise Value EBITDA 0.50
Price Book MRQ 0.73

Technical Indicators IFRX

For 52 Weeks

0.71 USD 2.82 USD
50 Day MA 1.15 USD
Shares Short Prior Month 1 184 656
200 Day MA 1.62 USD
Short Ratio 1.50
Shares Short 1 242 180
Short Percent 1.87 %